GlassScriptPhysician profile
Adam Robert Riordan
NPI 1508126988
$3,676.87
in general payments reported to CMS, 2019-2025
25 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $113 · 2021: $164 · 2022: $148 · 2023: $687 · 2024: $1,523 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Education: $14.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.64 |
| Education | $14.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.33 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $574.29 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $463.62 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $384.08 | 2019-2024 | |
| Qol Medical, LLC | $379.21 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.04 | 2019-2024 | Xifaxan, Plenvu |
| Regeneron Healthcare Solutions, INC. | $150.14 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $133.67 | 2022-2024 | Ibsrela |
| Gilead Sciences, INC. | $102.78 | 2019-2024 | |
| Braintree Laboratories, INC. | $94.21 | 2019-2023 | Sutab |
| Madrigal Pharmaceuticals | $71.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $69.39 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $63.76 | 2023-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $50.94 | 2024 | Voquezna |
| Sandoz INC. | $44.96 | 2023-2024 | Hyrimoz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.17 | 2023 | |
| Ucb, INC. | $36.47 | 2019 | |
| Celgene Corporation | $35.32 | 2021-2022 | |
| Boston Scientific Corporation | $24.72 | 2019-2020 | |
| Organon LLC | $21.41 | 2023 | Renflexis |
| Ipsen Biopharmaceuticals, INC | $19.32 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $15.82 | 2019 | |
| Merck Sharp & Dohme LLC | $15.62 | 2019 | |
| Celltrion USA INC. | $14.58 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Riordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.